At a glance
ClinicalIndex Comparison RecordN/ACompleted· 82 enrolled
Drug / intervention
MGMT methylation evaluationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients
In Brief
An observational study evaluating MGMT methylation evaluation for Ewing Sarcoma Family of Tumors. Completed, enrolled 82 participants across 5 sites in 2 countries.
Detailed Summary
This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated with the disease clinical data and with the disease response
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEwing Sarcoma Family of Tumors
CountriesItaly, United Kingdom
CollaboratorsRegione Emilia-Romagna
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedMay 2018
Primary CompletionDec 2018
Study CompletionJun 2019
TodayJul 2026
First PostedMay 31, 2018
Enrollment StartApr 15, 2014
Primary CompletionDec 31, 2018
Study CompletionJun 30, 2019
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 8.1 years ago
Interventions
MGMT methylation evaluationother
The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples